Similarly in Parkinson's patients, changes in polyamine levels also have been found, the decreased expression of polyamine metabolic enzyme SAT1 led to an increase in polyamine levels, which in turn reduced the cognitive performance of patients with Parkinson 's disease through the NMDAr pathway [47]. Here, SAT1 is linked to Parkinson disease.